Jevtana beats 2nd-line hormonals as 3rd therapy on pain relief and QOL

[Tall_Allen]

There was an update to the CARD trial that proved Jevtana was more effective than 2nd line hormonals (Zytiga or Xtandi) in its oncological effectiveness when used as the third treatment (after Taxotere and one of the 2nd-line hormonals). The new update shows that in terms of pain relief and quality of life (QOL), Jevtana was better.

Recall that even on a first treatment, the degree of side effects from docetaxel was no worse than Zytiga. The side effects were different in kind, but not in severity.

Here's the updated article, which includes both links to the CARD trial:

prostatecancer.news/2019/12...

[kick-prostate-cancer]

Thanks! You always provide such great information!

[StayingOptimistic in reply to kick-prostate-cancer]

Thank you, TA for posting. We do appreciate your help.

[Hidden]

Thanks. Good and easy to read summary with links for more details.

[Tall_Allen in reply to Hidden]

Thanks - I strive for easy to follow and understand. Between us (and anyone who reads this), I don't understand it when guys quote the entire body of an abstract as their post. To me, it makes it harder to follow - why don't they just provide the link? I guess in 20 years in business, it was drummed into my head to provide a short executive summary and provide back up as attachments. I wish this site allowed hyperlinks - I could make posts even shorter.

[SPEEDYX in reply to Tall_Allen]

So true totally concur as a president of a corporation that's what I look for and do!!

[SPEEDYX]

Straight forward treatment recommendations...excellent and important info...Thanks T.A.

[The_Dude]

Thanks so much — really informative.

[GoBucks]

Does this study provide any guide to those who are still hormone sensitive? I started with zytiga and have had no chemo. 33 months <0.01. When I become castrate resistant is Jevtana a good next step? I have multiple bone metastasis.

[Tall_Allen in reply to GoBucks]

Kind of. When Zytiga fails, one of the chemos or Xofigo and Provenge would be a good next step.

[V10fanatic in reply to Tall_Allen]

I hope they get the appropriate sequencing down soon. I'm an outlier in that I started with Lupron & Zytiga, then added Provenge and SBRT for a few bone mets. My PSA has been undetectable for about 5 months, and now Dr. Scholz is recommending that I get 4 sessions of Jevtana. His philosophy is that it's better to attack now, before the bad guys have a chance to regroup.

[tallguy2]

Thanks for posting this informative update.

I will add that, having been through 6 rounds of taxotere chemo and now on Zytiga plus Erleada for 8 months I’ll take the latter any day over chemotherapy’s side effects.

[dhccpa]

Thanks, TA. Lot of relevant stuff in there. Now--will my MO even be aware of it and follow it?

[Tall_Allen in reply to dhccpa]

I never hesitate to send doctors links to peer-reviewed clinical studies in quality journals (that's why I always provide those links in my articles). I assume they've seen it, but sometimes not. I just add a note "I'd like to discuss this at our next meeting."

[Cheerr]

Thanks for the info. Easy to read.

[Faith1111]

Thank you TA. We are blessed to have you on this forum

[Bob10]

Are Familiar with an AR alteration T878A, W742CN is there anything out there to stop the AR resistant prostate cancer

[Tall_Allen in reply to Bob10]

I'm not familiar with that particular AR mutation, but AR mutations are common as PC progresses. There are many experimental therapies targeting AR resistance including taxanes, BAT, phenelzine or clorgyline, niclosamine, ASC-J9, venetoclax, and indomethacin.

[Bob10]

Are Familiar with an AR alteration T878A, W742CN is there anything out there to stop the AR resistant prostate cancer

[Bob10 in reply to Bob10]

Which one do you looks worthwhile Tall allen

[Tall_Allen in reply to Bob10]

They all require more study